MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
BioDelivery Sciences International, Inc.
BDSI Details
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company specializing in developing treatments for those suffering from severe and debilitating chronic illnesses. BDSI uses its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology to develop and commercialize novel medicines that address critical unmet medical needs. BELBUCA (buprenorphine buccal film) for chronic pain and Symproic (naldemedine) for opioid-induced constipation are two of the company's product candidates.
Latest News:
Q3FY21 Results:
Key Risks:
Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation
(Analysis by Kalkine Group)
BDSI Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
The company’s performance in the quarter just gone by was moderate. Further, the company’s is taking relatively higher time to convert its investment in inventories into cash at bank compared to its peers. Further, BDSI's stock price increased 21.50% in the past and trading above 50-day SMA, however 200-day SMA could be a crucial resistance in the stock and 14-day RSI oscillator hovering in a overbought zone at 72.18, implies a potential consolidation from the current trading level.
Considering the uptick in the stock price, current valuation, and technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 3.646, down 1.19%, as of January 25, 2022, 01:59 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.